EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH : A Retrospective Multinational Cohort Study From North America and Europe

Abdallah Hussein iD, Ameer Awashra iD, Islam Rajab iD, Mohammad Bdair iD, Dawoud Hamdan iD, Ahmad Nouri iD, Elaf Khatib, Ghiras Khatib, Nyan Latt

Endocrinology, Diabetes & Metabolism · 2025

DOI: 10.1002/edm2.70075 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2025. Verfasst von Abdallah Hussein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Virtua Health Inc., Voorhees, New Jersey, USA. Hauptthemen laut MEDLINE: Bariatric Surgery, Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) that can progress to cirrhosis and hepatocellular carcinoma (HCC). Obesity is a major risk factor for NASH, and metabolic interventions such as bariatric surgery (BS) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been explored for their impact on liver‐related outcomes. This study evaluates the comparative effectiveness of BS and GLP‐1 RAs in reducing the incidence of new‐onset NASH and related hepatic complications.

Methods

This was a large, population‐based, retrospective cohort using data from the TriNetX platform. Adult patients with a body mass index (BMI, of 35 or greater and without a history of NAFLD/NASH (without cirrhosis) who underwent BS versus GLP‐1RA between January 1, 2014 and December 31, 2019, were included. Patients in the BS group were matched with patients in the GLP‐1RA group according to age, demographics, comorbidities and medication by using 1:1 propensity matching.

Results

Among 180,022 eligible adults, 143,404 underwent BS, while 36,618 received GLP‐1 RA therapy. Following propensity score matching, 33,594 patients in the BS group (mean age 49.1 ± 13.2 years; 72.73% female) were matched to an equal number of individuals in the GLP‐1 RA group (mean age 48.9 ± 14.0 years; 72.41% female). Compared to those receiving GLP‐1 RA therapy, patients who underwent BS had a significantly lower risk of HCC (HR, 0.304; 95% CI, 0.099–0.931), which showed the strongest protective effect, followed by a substantial reduction in NASH (HR, 0.509; 95% CI, 0.469–0.551). The reduction in liver cirrhosis risk was not statistically significant (HR, 0.865; 95% CI, 0.696–1.075). These associations remained across follow‐up periods of 1, 3, 5 and 7 years.

Conclusions

These findings suggest that BS was significantly associated with lower risk of new onset of NASH/NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryNon-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide-1 Receptor AgonistsObesityHumansFemaleMaleRetrospective StudiesMiddle AgedAdultEuropeNorth AmericaTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 receptor agonistsbariatric surgeryhepatocellular carcinomaliver cirrhosismetabolic dysfunctionnonalcoholic steatohepatitis (NASH)obesitypropensity score matchingreal‐world dataretrospective cohort study

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Internal Medicine Department, Virtua Health Inc., Voorhees, New Jersey, USA.
  • Department of Medicine, An Najah National University, Nablus, Palestine.
  • Internal Medicine Department, St. Joseph's University Medical Center, Paterson, New Jersey, USA.
  • College of Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • School of Public Health, Drexel University, Philadelphia, Pennsylvania, USA.
  • Gastroenterology and Hepatology, Virtua Health Inc., Voorhees, New Jersey, USA.

ORCID-Profile: Abdallah Hussein, Ameer Awashra, Islam Rajab, Mohammad Bdair, Dawoud Hamdan, Ahmad Nouri

Zitieren

APA

Hussein, A., Awashra, A., Rajab, I., Bdair, M., Hamdan, D., Nouri, A., Khatib, E., Khatib, G., & Latt, N. (2025). Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH : A Retrospective Multinational Cohort Study From North America and Europe. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70075

Vancouver

Hussein A, Awashra A, Rajab I, Bdair M, Hamdan D, Nouri A, et al. Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH : A Retrospective Multinational Cohort Study From North America and Europe. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70075

BibTeX
@article{Hussein2025,
  author = {Hussein, Abdallah and Awashra, Ameer and Rajab, Islam and Bdair, Mohammad and Hamdan, Dawoud and Nouri, Ahmad and Khatib, Elaf and Khatib, Ghiras and Latt, Nyan},
  title = {Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH : A Retrospective Multinational Cohort Study From North America and Europe},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  doi = {10.1002/edm2.70075}
}
Kostenlos starten →